Background: Development of albuminuria and arterial stiffness in Munich Wistar Frömter (MWF) rats, a model of chronic kidney disease, is related to alterations in extracellular matrix, increased oxidative stress, and endothelial dysfunction. Finerenone (FIN), a novel, nonsteroidal, potent, and selective mineralocorticoid receptor antagonist, improves endothelial dysfunction through enhancing nitric oxide (NO) bioavailability and decreasing superoxide anion levels due to an upregulation in vascular and renal superoxide dismutase activity. We hypothesize that FIN reduces arterial stiffness in this model associated to the reduction in albuminuria and matrix metalloproteinase (MMP)-2/9 activity.
Methods: Twelve-week-old MWF rats with established albuminuria and age-matched normoalbuminuric Wistar (W) rats were treated with FIN (10 mg/kg/day, once-daily oral gavage) or with vehicle (control, C) for 4 weeks.
Results: Arterial stiffness was significantly higher in mesenteric arteries (MA) of MWF-C as compared to W-C. FIN treatment significantly lowered β-index, a measure of intrinsic stiffness independent of geometry, in MWF (βMWF-FIN = 7.7 ± 0.4 vs. βMWF-C = 9.2 ± 0.5, p < 0.05) positively correlating with urinary albumin excretion. Elastin fenestrae area in the internal elastic lamina of MA from MWF-FIN was significantly larger (+377%, p < 0.05). FIN increased plasma pro-MMP-2 and decreased plasma MMP-2 and MMP-9 activities, correlating with reductions in β-index. MA from MWF-FIN exhibited higher NO bioavailability and reduced superoxide anion levels compared to MWF-C.
Conclusion: FIN treatment reduces intrinsic arterial stiffness in MA from MWF rats associated with changes in elastin organization, normalization of MMP-2 and MMP-9 activities, and reduction of oxidative stress. Moreover, reduction of arterial stiffness correlates with reduction in albuminuria.
Keywords: Albuminuria; Chronic kidney disease; Intrinsic arterial stiffness; Mesenteric arteries; Metalloproteinases; Mineralocorticoid receptor antagonists.
© 2020 S. Karger AG, Basel.
Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress.Front Pharmacol. 2018 Oct 9;9:1131. doi: 10.3389/fphar.2018.01131. eCollection 2018. Front Pharmacol. 2018. PMID: 30356804 Free PMC article.
Genetic predisposition to albuminuria is associated with increased arterial stiffness: role of elastin.Br J Pharmacol. 2015 Sep;172(17):4406-18. doi: 10.1111/bph.13223. Epub 2015 Jul 21. Br J Pharmacol. 2015. PMID: 26075500 Free PMC article.
Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria.Clin Sci (Lond). 2016 Apr 1;130(7):525-38. doi: 10.1042/CS20150517. Epub 2016 Jan 5. Clin Sci (Lond). 2016. PMID: 26733721
Impaired coronary endothelial function in a rat model of spontaneous albuminuria.Kidney Int. 2002 Jul;62(1):181-91. doi: 10.1046/j.1523-1755.2002.00431.x. Kidney Int. 2002. PMID: 12081577
Mechanisms of cardiovascular remodeling in hyperhomocysteinemia.Antioxid Redox Signal. 2011 Oct 1;15(7):1927-43. doi: 10.1089/ars.2010.3721. Epub 2011 Apr 21. Antioxid Redox Signal. 2011. PMID: 21126196 Free PMC article. Review.